What the Options Market Tells Us About Bristol-Myers Squibb

Financial giants have made a conspicuous bullish move on Bristol-Myers Squibb. Our analysis of options history for Bristol-Myers Squibb BMY revealed 8 unusual trades.

Delving into the details, we found 75% of traders were bullish, while 25% showed bearish tendencies. Out of all the trades we spotted, 4 were puts, with a value of $629,040, and 4 were calls, valued at $142,485.

Predicted Price Range

Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $40.0 to $62.5 for Bristol-Myers Squibb during the past quarter.

Insights into Volume & Open Interest

Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Bristol-Myers Squibb's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Bristol-Myers Squibb's substantial trades, within a strike price spectrum from $40.0 to $62.5 over the preceding 30 days.

Bristol-Myers Squibb Option Volume And Open Interest Over Last 30 Days

Noteworthy Options Activity:

About Bristol-Myers Squibb

Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the U.S., showing a higher dependence on the U.S. market than most of its peer group.

Having examined the options trading patterns of Bristol-Myers Squibb, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance

Bristol-Myers Squibb's Current Market Status

• Currently trading with a volume of 4,070,799, the BMY's price is up by 0.71%, now at $49.79.
• RSI readings suggest the stock is currently is currently neutral between overbought and oversold.
• Anticipated earnings release is in 69 days.

What Analysts Are Saying About Bristol-Myers Squibb

A total of 2 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $52.5.

• An analyst from Wells Fargo persists with their Equal-Weight rating on Bristol-Myers Squibb, maintaining a target price of $51.
• Reflecting concerns, an analyst from Redburn Atlantic lowers its rating to Neutral with a new price target of $54.

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Bristol-Myers Squibb options trades with real-time alerts from Benzinga Pro.